The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra®) on contraceptive efficacy

被引:63
作者
Archer, DF
Cullins, V
Creasy, GW
Fisher, AC [1 ]
机构
[1] Ortho McNeil Pharmaceut Inc, Raritan, NJ 08869 USA
[2] Eastern Virginia Med Sch, Clin Res Ctr, Contracept Res & Dev Program, Norfolk, VA 23501 USA
[3] Planned Parenthood Federat Amer Inc, New York, NY USA
[4] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ 08869 USA
关键词
Ortho Evra; Triphasil; compliance; perfect dosing; contraceptive efficacy; Pearl Index;
D O I
10.1016/j.contraception.2003.10.006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The contraceptive efficacy of perfect dosing cycles and imperfect dosing cycles has not been described previously. Method compliance determines the proportion of perfect and imperfect dosing cycles, and together can form the basis for evaluating differences in efficacy based on differences in compliance. Materials and methods: The transdermal contraceptive delivery system (Ortho Evra(R)) has been studied in a North American randomized trial vs. an oral contraceptive (OC) and in total has been evaluated in 3319 women in contraceptive clinical trials. This article explores the impact of perfect vs. imperfect compliance with the contraceptive method on contraceptive efficacy. Previously published data for a transdermal system (Patch, n = 812) and OC (Triphasil(R), n = 605) users from the North American comparative study were reanalyzed to determine the effect of imperfect use on the contraceptive efficacy of the different methods. Results: Contraceptive efficacy was significantly better (p = 0.007) in cycles with perfect dosing (Pearl Index = 0.83) compared to those with imperfect dosing (Pearl Index = 6.32) for both methods. This difference is homogeneous (p = 0.62) across the Patch and OC groups. Pooled data for all Patch users confirm that perfect dosing cycles are associated with significantly better efficacy than imperfect dosing cycles (p = 0.047). In addition, compliance did not vary by age in the pooled Patch data, which are in agreement with the previously published Patch data from the comparative study. In the comparative study, the percentage of cycles with perfect dosing was significantly higher with the Patch than with the OC (88.7% vs. 79.2%, p < 0.001), and was consistently high in all age groups (range, 89.6-91.8%). By contrast, among OC users, the percentage of cycles with perfect dosing increased with increasing age (p < 0.001) from 67.7% in users aged 18-20 years to more than 80% in those aged 30 years and older. Conclusion: In conclusion, deviations from perfect use (whether corrected or not) of a transdermal contraceptive system and of an OC increase contraceptive failures by approximately 5-10-fold when compared to perfect use. The weekly change schedule of the transdermal contraceptive delivery system is associated with a significantly greater proportion of cycles in which there is perfect dosing compared to an OC. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 20 条
[1]  
Archer DF, 2002, FERTIL STERIL, V77, pS27
[2]   Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial [J].
Audet, MC ;
Moreau, M ;
Koltun, WD ;
Waldbaum, AS ;
Shangold, G ;
Fisher, AC ;
Creasy, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2347-2354
[3]  
Benagiano G., 1992, Advances in Contraception, V8, P47, DOI 10.1007/BF01849450
[4]   Contraceptive compliance [J].
Dardano, KL ;
Burkman, RT .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2000, 27 (04) :933-+
[5]   Preliminary examination of oral contraceptive use among university-aged females [J].
Fletcher, PC ;
Bryden, PJ ;
Bonin, E .
CONTRACEPTION, 2001, 63 (04) :229-233
[6]   Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth [J].
Fu, HS ;
Darroch, JE ;
Haas, T ;
Ranjit, N .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (02) :56-63
[7]  
Fuchs N, 1996, Eur J Contracept Reprod Health Care, V1, P275, DOI 10.3109/13625189609150670
[8]  
HEDON B, 2000, INT J GYNECOL OBS S1, V70, P78
[9]  
HINTZE JL, 2000, PASS 2000 USERS GUID
[10]   Injectable long-acting contraceptives [J].
Kaunitz, AM .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2001, 44 (01) :73-91